{"id":392814,"date":"2020-12-03T09:20:28","date_gmt":"2020-12-03T14:20:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=392814"},"modified":"2020-12-03T09:20:28","modified_gmt":"2020-12-03T14:20:28","slug":"senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/","title":{"rendered":"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <b>Highlights:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>The first hospitalized patient with severe COVID-19, treated under an eIND was discharged in 5 days after being treated with Silmitasertib.<\/b>\n        <\/li>\n<li>\n          <b>The first patient with moderate COVID-19 has enrolled into this clinical trial at the Center for Advanced Research and Education (CARE), <span class=\"xn-location\">Georgia<\/span>.<\/b>\n        <\/li>\n<li>\n          <b>An additional study involving multiple centers in Banner &#8211; <\/b><br \/>\n          <b>University Medical Center Phoenix (BUMCP) will treat hospitalized COVID-19 patients<\/b><br \/>\n          <b>.\u00a0<\/b>\n        <\/li>\n<\/ul>\n<p>\n        <span class=\"xn-location\">TAIPEI<\/span> and <span class=\"xn-location\">SAN DIEGO<\/span>, <span class=\"xn-chron\">Dec. 3, 2020<\/span> \/PRNewswire\/ &#8212; Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient was enrolled into a Phase II\u00a0investigator-initiated trial (IIT)\u00a0of its anti-SARS-CoV-2 investigational drug, Silmitasertib, as a treatment for coronavirus disease (COVID-19) at the Center for Advanced Research and Education (CARE) in <span class=\"xn-location\">Gainesville, Georgia<\/span>. <\/p>\n<p>This IIT\u00a0is a phase II single-center, open-label, randomized-controlled interventional prospective study. It is designed to enroll 20 patients with moderate COVID-19, where half will receive Silmitasertib for 14 days. The study&#8217;s objectives are to assess the safety and tolerability of the drug product, recovery time of the patient, and possible clinical benefits of treatment with Silmitasertib. <\/p>\n<p>&#8220;We are encouraged by the quick recovery of the first hospitalized patient with severe COVID-19 who received Silmitasertib under an emergency IND. We also believe Silmitasertib has the potential to be an effective outpatient treatment for patients with moderate COVID-19,&#8221; said Dr. <span class=\"xn-person\">John Soong<\/span>, Chief Medical Officer of Senhwa Biosciences. <\/p>\n<p>Senhwa&#8217;s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2) pathway, where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. It challenges the virus&#8217; ability to replicate quickly and spread to nearby healthy cells. &#8220;Silmitasertib&#8217;s mechanism of action by CK2 inhibition is a unique pathway to target SARS-CoV-2 infection which has promise to combat COVID-19,&#8221; said Dr. Chris Recknor,\u00a0Principal Investigator of this IIT trial. <\/p>\n<p>A separate Phase II IIT led by Dr. <span class=\"xn-person\">Marilyn Glassberg Csete<\/span> at Banner \u2013 University Medical Center Phoenix <span id=\"spanHghlt1fcf\">is to be initiated<\/span> as FDA has granted study may proceed letter to Banner on <span class=\"xn-chron\">November 26<\/span>, 2020.\u00a0The Banner trial will seek to enroll 40 hospitalized patients with severe COVID-19. <\/p>\n<p>\n        <b>About\u00a0Silmitasertib<\/b>\n      <\/p>\n<p>Silmitasertib is a first-in-class small molecule drug that targets CK2 and acts as a CK2-inhibitor. Silmitasertib is safe and well-tolerated in humans. To date, three Phase I trials of Silmitasertib in cancer patients have been completed; currently, there is one ongoing Phase I and two ongoing Phase II studies. In <span class=\"xn-chron\">December 2016<\/span>, Silmitasertib was granted Orphan Drug Designation by the U.S. FDA for the treatment of Cholangiocarcinoma. In <span class=\"xn-chron\">July 2020<\/span>, Silmitasertib was granted Rare Pediatric Disease Designation (RPD) to treat Medulloblastoma by the U.S. FDA. An eIND was\u00a0granted by the U.S. FDA on <span class=\"xn-chron\">August 27, 2020<\/span>, to Dr. Rayyan at BUMCP to treat a patient with severe COVID-19. <\/p>\n<p>\n        <b>About Senhwa Biosciences<\/b>\n      <\/p>\n<p>Senhwa Biosciences, Inc. is a leading clinical-stage company focusing on developing first-in-class, next-generation DDR therapeutics for patients with unmet medical needs in oncology. Headquartered in <span class=\"xn-location\">Taiwan<\/span>, with an operational base in <span class=\"xn-location\">San Diego, California<\/span>, Senhwa is well-positioned to oversee the development of its compounds.<\/p>\n<p>Development is currently focused on two lead products: Silmitasertib (CX-4945) and Pidnarulex (CX-5461), both with novel mechanisms of action and for multiple indications. Clinical trials are ongoing in <span class=\"xn-location\">Australia<\/span>, <span class=\"xn-location\">Canada<\/span>, <span class=\"xn-location\">United States<\/span>, Korea, and <span class=\"xn-location\">Taiwan<\/span>, with more currently in development.<\/p>\n<p>Visit\u00a0Senhwa Biosciences for more details: <a target=\"_blank\" href=\"http:\/\/www.senhwabio.com\/\" rel=\"nofollow noopener noreferrer\">www.senhwabio.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK12121&amp;sd=2020-12-03\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19-301185813.html\">http:\/\/www.prnewswire.com\/news-releases\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19-301185813.html<\/a><\/p>\n<p>SOURCE  Senhwa Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=HK12121&amp;Transmission_Id=202012030917PR_NEWS_USPR_____HK12121&amp;DateId=20201203\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Highlights: The first hospitalized patient with severe COVID-19, treated under an eIND was discharged in 5 days after being treated with Silmitasertib. The first patient with moderate COVID-19 has enrolled into this clinical trial at the Center for Advanced Research and Education (CARE), Georgia. An additional study involving multiple centers in Banner &#8211; University Medical Center Phoenix (BUMCP) will treat hospitalized COVID-19 patients .\u00a0 TAIPEI and SAN DIEGO, Dec. 3, 2020 \/PRNewswire\/ &#8212; Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient was enrolled into a Phase II\u00a0investigator-initiated trial (IIT)\u00a0of its anti-SARS-CoV-2 investigational drug, Silmitasertib, as a treatment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-392814","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Highlights: The first hospitalized patient with severe COVID-19, treated under an eIND was discharged in 5 days after being treated with Silmitasertib. The first patient with moderate COVID-19 has enrolled into this clinical trial at the Center for Advanced Research and Education (CARE), Georgia. An additional study involving multiple centers in Banner &#8211; University Medical Center Phoenix (BUMCP) will treat hospitalized COVID-19 patients .\u00a0 TAIPEI and SAN DIEGO, Dec. 3, 2020 \/PRNewswire\/ &#8212; Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient was enrolled into a Phase II\u00a0investigator-initiated trial (IIT)\u00a0of its anti-SARS-CoV-2 investigational drug, Silmitasertib, as a treatment &hellip; Continue reading &quot;Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-03T14:20:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK12121&amp;sd=2020-12-03\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19\",\"datePublished\":\"2020-12-03T14:20:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/\"},\"wordCount\":595,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK12121&amp;sd=2020-12-03\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/\",\"name\":\"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK12121&amp;sd=2020-12-03\",\"datePublished\":\"2020-12-03T14:20:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK12121&amp;sd=2020-12-03\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK12121&amp;sd=2020-12-03\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/","og_locale":"en_US","og_type":"article","og_title":"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19 - Market Newsdesk","og_description":"PR Newswire Highlights: The first hospitalized patient with severe COVID-19, treated under an eIND was discharged in 5 days after being treated with Silmitasertib. The first patient with moderate COVID-19 has enrolled into this clinical trial at the Center for Advanced Research and Education (CARE), Georgia. An additional study involving multiple centers in Banner &#8211; University Medical Center Phoenix (BUMCP) will treat hospitalized COVID-19 patients .\u00a0 TAIPEI and SAN DIEGO, Dec. 3, 2020 \/PRNewswire\/ &#8212; Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient was enrolled into a Phase II\u00a0investigator-initiated trial (IIT)\u00a0of its anti-SARS-CoV-2 investigational drug, Silmitasertib, as a treatment &hellip; Continue reading \"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-03T14:20:28+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK12121&amp;sd=2020-12-03","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19","datePublished":"2020-12-03T14:20:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/"},"wordCount":595,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK12121&amp;sd=2020-12-03","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/","name":"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK12121&amp;sd=2020-12-03","datePublished":"2020-12-03T14:20:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK12121&amp;sd=2020-12-03","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK12121&amp;sd=2020-12-03"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-the-first-patient-enrolled-in-an-investigator-initiated-trial-of-silmitasertib-as-a-treatment-for-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=392814"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392814\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=392814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=392814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=392814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}